{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:10Z","timestamp":1786994410100,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.msard.2020.102637","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T02:11:49Z","timestamp":1606097509000},"page":"102637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60"],"prefix":"10.1016","volume":"47","author":[{"given":"Le H.","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie M.","family":"Hersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102637_bib0001","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1007\/s00415-015-7842-0","article-title":"High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991\u20132010)","volume":"262","author":"Kingwell","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0002","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1212\/WNL.0000000000005331","article-title":"Temporal trends in multiple sclerosis prevalence and incidence in a large population","volume":"90","author":"Rotstein","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102637_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2005.08.006","article-title":"Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis","volume":"239","author":"Tortorella","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2020.102637_bib0004","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2020.102637_bib0005","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2147\/NDT.S140634","article-title":"The role of microglia in multiple sclerosis","volume":"13","author":"Luo","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.msard.2020.102637_bib0006","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00109-018-1686-x","article-title":"Targeting senescence to delay progression of multiple sclerosis","volume":"96","author":"Oost","year":"2018","journal-title":"J Mol Med"},{"key":"10.1016\/j.msard.2020.102637_bib0007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.msard.2020.102637_bib0008","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2020.102637_bib0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0011","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamaneurol.2019.0330","article-title":"Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades","volume":"76","author":"Beiki","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0012","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1177\/1352458516687402","article-title":"Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS","volume":"23","author":"Capra","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2020.102637_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long\u2010term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0014","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/1352458512463764","article-title":"Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs","volume":"19","author":"Tedeholm","year":"2013","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2020.102637_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00632","article-title":"Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)","volume":"11","author":"Mowry","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0016","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12325-019-00958-x","article-title":"Multiple Sclerosis Performance Test: Technical Development and Usability","volume":"36","author":"Rhodes","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.msard.2020.102637_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1352458516688955","article-title":"Processing speed test: Validation of a self-administered, iPad(\u00ae)-based tool for screening cognitive dysfunction in a clinic setting","author":"Rao","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2020.102637_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14162","article-title":"Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules","author":"Rao","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0019","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-13-37","article-title":"Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis","author":"Learmonth","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0020","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QOL","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology"},{"issue":"S2","key":"10.1016\/j.msard.2020.102637_bib0021","first-page":"78","article-title":"Multiple sclerosis performance test (MSPT): a demographically stratified normative database (N\u00a0=\u00a0517) of healthy subjects ages 15-89 to aid clinical interpretation of MS patient neuroperformance","volume":"25","author":"Sokolowski","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2020.102637_bib0022","article-title":"Vascular Comorbidity is Associated with Lower Brain Volumes in a Large Multiple Sclerosis Cohort","author":"Fitzgerald","year":"2020","journal-title":"ANA Annu Meet Oct 4-9"},{"key":"10.1016\/j.msard.2020.102637_bib0023","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.msard.2020.102637_bib0024","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1352458512451510","article-title":"Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis","volume":"19","author":"Tutuncu","year":"2013","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2020.102637_bib0025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0026","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2020.102637_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/NRE-2004-19107","article-title":"Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study","volume":"19","author":"Minden","year":"2004","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.msard.2020.102637_bib0028","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.0b013e3182872855","article-title":"Disability in multiple sclerosis","volume":"80","author":"Kister","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102637_bib0029","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7224\/1537-2073.2012-046","article-title":"Factors Associated with Health-Related Quality of Life Among Older People with Multiple Sclerosis","volume":"16","author":"Buhse","year":"2014","journal-title":"Int J MS Care"},{"key":"10.1016\/j.msard.2020.102637_bib0030","article-title":"Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis","author":"Miller","year":"2015","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2020.102637_bib0031","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458512437814","article-title":"Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia","volume":"18","author":"Marrie","year":"2012","journal-title":"Mult Scler J"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:53:20Z","timestamp":1761900800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":31,"alternative-id":["S2211034820307112"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102637","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102637"}}